Jiangsu Hengrui Pharmaceuticals (SHA:600276) unit Ruishi Biopharmaceuticals obtained the approval of China's drug regulator to begin clinical trials for RSS0393 Latex.
The drug is indicated to treat atopic dermatitis, according to a Friday filing with the Shanghai bourse.
Shares of the pharmaceutical company were down 1% Friday.